Positive reactions for both Cyfra21-1 and CA125 indicate worst prognosis in non-small cell lung cancer

Anticancer Research

Volumn 23, Issue 3 C, 2003, Pages 2869-2874

  Ando, Soichiro ^a   Kimura, Hideki ^a   Iwai, Naomichi ^a   Yamamoto, Naotaka ^a   Iida, Tomohiko ^a  

^a CHIBA CANCER CENTER   (Japan)

Author keywords

CA125; Cyfra 21 1; Non small cell lung cancer; Prognosis

Indexed keywords

CA 125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CYTOKERATIN 19 FRAGMENT; SQUAMOUS CELL CARCINOMA ANTIGEN; TUMOR MARKER;

ADENOCARCINOMA; ARTICLE; BLOOD LEVEL; CANCER CLASSIFICATION; CANCER INCIDENCE; CANCER PATIENT; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE SEVERITY; FEMALE; HAZARD ASSESSMENT; HUMAN; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; MAJOR CLINICAL STUDY; MALE; MEDICAL ASSESSMENT; MULTIVARIATE ANALYSIS; PRIORITY JOURNAL; PROGNOSIS; RETROSPECTIVE STUDY; TISSUE SECTION;

ADULT; AGED; AGED, 80 AND OVER; ANTIGENS, NEOPLASM; CA-125 ANTIGEN; CARCINOEMBRYONIC ANTIGEN; CARCINOMA, NON-SMALL-CELL LUNG; FEMALE; HUMANS; KERATINS; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; RETROSPECTIVE STUDIES; SERPINS; TUMOR MARKERS, BIOLOGICAL;

EID: 0041622688     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (25)

1. Pujol JL, Grenier J, Parrat E et al: Cytokeratins as serum markers in lung cancer: A comparison of CYFRA21-1 and TPS. Am J Respir Crit Care Med 154: 725-33, 1996.
2. Nisman B, Lafair J, Heching N et al: Evaluation of tissue polypeptide specific antigen, CYFRA 21-1, and carcinoembryonic antigen in non-small cell lung carcinoma. Cancer 82: 1850-9, 1998.
3. Nisman B, Amir G, Lafair J et al: Prognostic value of CYFRA 21-1, TPS and CEA in different histologic types of non-small cell lung cancer. Anticancer Res 19: 3549-52, 1999.
4. Bréchot JM, Chevret S, Nataf J et al: Diagnostic and prognostic value of Cyfra 21-1 compared with other tumour markers in patients with non-small cell lung cancer: A prospective study of 116 patients. Eur J Cancer 82: 1850-9, 1998.
5. Hatzakis KD, Froudarakis ME, Bourous D, Tzannakis N, Karkavitsas N and Siafakas NM: Prognostic value of serum tumor markers in patients with lung cancer. Respiration 69: 25-29, 2002.
6. Pujol JL, Grenier J, Daurès JP, Daver A, Pujol H and Michel FB: Serum fragment of cytokeratin subunit 19 measured by CYFRA21-1 immunoradiometric assay as a marker of lung cancer. Cancer Res 53: 61-66, 1993.
7. Wieskopf B, Demangeat C, Purohit A et al: Cyfra 21-1 as a biological marker of non-small cell lung cancer. Evaluation of sensitivity, specificity and prognostic role. Chest 108: 163-169, 1995.
8. Foa P, Fornier M, Miceli R et al: Tumour markers CEA, NSE, SCC, TPA and CYFRA21.1 in resectable non-small cell lung cancer. Anticancer Res 19: 3613-3618, 1999.
9. Niklinski J, Furman M, Burzykowski T et al: Preoperative CYFRA 21-1 level as prognostic indicator in resected primary squamous cell lung cancer. Br J Cancer 74: 956-960-1254, 1996.
10. Diez M, Torres A, Maestro ML et al: Prediction of survival and recurrence by serum and cytosolic levels of CEA, CA125 and SCC antigens in respectable non-small cell lung cancer. Br J Cancer 73: 1248-1254, 1996.
11. Kimura Y, Fujii T, Hamamoto K, Miyagawa N, Kataoka M and Iio A: Serum CA125 level is a good prognostic indicator in lung cancer. Br J Cancer 62: 676-678, 1990.
12. Suzuki K, Nagai K, Yoshida J et al: Prognostic factor in clinical stage I non-small cell lung cancer. Ann Thorac Surg 67: 927-932, 1999.
13. Body JJ, Sculier JP, Raymakers N et al: Evaluation of squamous cell carcinoma antigen as a new marker for lung cancer. Cancer 65: 1552-1556, 1990.
14. Icard P, Regnard JF, Essomba A, Panebianco V, Magdeleinat P and Levasseur P: Preoperative carcinoembryonic antigen level as a prognostic indicator in resected primary lung cancer. Ann Thorac Surg 58: 811-814, 1994.
15. Niklinski J, Furman M, Laudanski J and Kozlowski M: Evaluation of squamous cell carcinoma antigen (SCC-Ag) in the diagnosis and follow-up of patients with non-small cell lung carcinoma. Neoplasma 39: 279-282, 1992.
16. Sanchez De Cos J, Masa F, de la Cruz JL, Disdier C and Vergara C: Squamous cell carcinoma antigen (SCC Ag) in the diagnosis and prognosis of lung cancer. Chest 47: 535-537, 1994.
17. Janssen-Heijnen MLG and Coebergh JWW: Trends in incidence and prognosis of the histological subtypes of lung cancer in North America, Australia, New Zealand and Europe. Lung Cancer 31: 123-137, 2001.
18. Harkness EF, Brewster DH, Kerr KM, Fergusson RJ and Macfarlane GJ: Changing trends in incidence of lung cancer by histologic type in Scotland. Int J Cancer 102: 179-183, 2002.
19. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD and Heath CW Jr: Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89: 1580-1586, 1997.
20. Sobin LH and Wittekind Ch: UICC. TNM Classification of malignant tumours. New York: Wiley-Liss Inc., 1997.
21. Metz CE: Basic principles of ROC analysis. Semin Nucl Med 8: 283-294, 1978.
22. Kaplan E and Meier P: Non-parametric estimation from incomplete observations. J Am Stat Assoc 53: 457-481, 1958.
23. Peto R and Peto J: Asymptotically efficient rank invariant test procedures (with discussion). J R Stat Soc A 135: 185-206, 1972.
24. Cox Dr: Regression models and life tables (with discussion). J R Stat Soc B 34: 187-220, 1972.
25. Ando S, Kimura H, Iwai N et al: Optimal combination of seven tumour markers in prediction of advanced stage at first examination of patients with non-small cell lung cancer. Anticancer Res 21: 3085-3092, 2001.